CONCISE REPORT

Antimalarials may influence the risk of malignancy in systemic lupus erythematosus

G Ruiz-Irastorza¹, A Ugarte¹, M V Egurbide¹, M Garmendia¹, J I Pijoan², A Martinez-Berriotxoa¹, C Aguirre¹

¹ Department of Internal Medicine, Hospital de Cruces, University of the Basque Country, Bizkaia, Spain
² Clinical Epidemiology Unit, Hospital de Cruces, University of the Basque Country, Bizkaia, Spain

Correspondence to:
Dr G Ruiz-Irastorza
Servicio de Medicina Interna, Hospital de Cruces, 48903-Bizkaia, Spain; r.irastorza{at}euskalnet.net

Background: Recent studies suggest that antimalarials have antineoplastic properties.

Objective: To investigate whether antimalarials decrease the risk of cancer in systemic lupus erythematosus (SLE).

Methods: An observational prospective cohort study was carried out. 235 patients were included in the study at the time of diagnosis (American College of Rheumatology criteria). The end point was the diagnosis of cancer. Kaplan–Meier cancer-free survival curves for patients treated and not treated with antimalarials were compared. A Cox proportional hazards model was fitted, with cancer as the dependent variable. Age at diagnosis, gender, treatment with azathioprine, cyclophosphamide and methotrexate, smoking, Systemic Lupus International Collaborating Clinics (SLICC) Damage Index 6 months after diagnosis, year of diagnosis and treatment with antimalarials were entered as independent variables.

Results: 209 (89%) patients were women. 233 (99%) patients were white. Mean (SD) age at diagnosis was 37 (16) years. Median (range) follow-up was 10 (1–31) years. 156 (66%) patients had ever received antimalarials. 2/156 (1.3%) ever-treated patients compared with 11/79 (13%) never-treated patients had cancer (p<0.001). Cumulative cancer-free survival in treated and not treated patients was 0.98 and 0.73, respectively (p<0.001). Adjusted hazard ratio for cancer among malaria drug users compared with non-users was 0.15 (95% CI 0.02 to 0.99).

Conclusions: This study launches the hypothesis of a protective action of antimalarials against cancer in patients with SLE. This effect should be confirmed in larger multicentre studies.

Abbreviations: SDI, Systemic Lupus International Collaborating Clinics (SLICC) Damage Index; SLE, systemic lupus erythematosus

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Lofstrom, B., Backlin, C., Sundstrom, C., Hellstrom-Lindberg, E., Ekbom, A., Lundberg, I. E. (2009). Myeloid leukaemia in systemic lupus erythematosus--a nested case-control study based on Swedish registers. Rheumatology (Oxford) 48: 1222-1226 [Abstract] [Full Text]  
• Gayed, M, Bernatsky, S, Ramsey-Goldman, R, Clarke, A., Gordon, C (2009). Lupus and cancer. Lupus 18: 479-485 [Abstract]  
• Ruiz-Irastorza, G., Egurbide, M. V., Olivares, N., Martinez-Berriotxoa, A., Aguirre, C. (2008). Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology (Oxford) 47: 920-923 [Abstract] [Full Text]  
• Ruiz-Irastorza, G, Khamashta, M. (2008). Hydroxychloroquine: the cornerstone of lupus therapy. Lupus 17: 271-273  
• Siso, A, Ramos-Casals, M, Bove, A, Brito-Zeron, P, Soria, N, Munoz, S, Testi, A, Plaza, J, Sentis, J, Coca, A (2008). Previous antimalarial therapy in patients diagnosed with lupus nephritis: Influence on outcomes and survival. Lupus 17: 281-288 [Abstract]  
• Doria, A, Briani, C (2008). Lupus: improving long-term prognosis. Lupus 17: 166-170 [Abstract]  
• Bernatsky, S, Clarke, A, Suissa, S (2008). Antimalarial drugs and malignancy: no evidence of a protective effect in rheumatoid arthritis. Ann Rheum Dis 67: 277-278 [Full Text]